The federal government called for a “pause” on injections of the single-dose Johnson & Johnson coronavirus vaccine this week after six U.S. women between the ages of 18 and 48 experienced a rare, severe form of blood clotting six to 13 days after receiving their inoculations.
One woman, a 45-year-old from Virginia, has died. Another is in critical condition. And there may be more cases out there we haven’t even heard of.
It’s concerning — especially for young women who recently received the J&J COVID-19 vaccine — but the nationwide call to stop using the vaccine until medical professionals have taken a more in-depth look at what’s happening should make us feel more secure in our nation’s COVID-19 vaccine rollout.
As it turns out, one of the main reasons for the pause was to alert doctors that they should not use the common blood thinner heparin to treat the form of blood clotting in the brain seen after the J&J vaccine, as heparin could make the problem even worse.
As a vascular medicine specialist told the Detroit Free Press this week: “What we are learning about these blood clots and how they might be associated with the use of the AstraZeneca vaccine in Canada and Europe and now it sounds like potentially with the Johnson & Johnson vaccine here is, we actually need … to use a different form of a blood thinner. That’s sort of the critical piece for doctors to know about.”